Biomarkers of Neural tube defects

Definition and Diagnostic Overview

Definition: Biomarkers in neural tube defects (NTDs) represent biochemical substances, genetic indicators, or epigenetic signals measured in maternal serum, amniotic fluid, or neonatal specimens that indicate failure of neural tube closure during early embryonic development (days 21–28 post-conception).
Classification:
- Screening Biomarkers: Maternal serum analytes used in the first and second trimesters.
- Diagnostic/Confirmatory Biomarkers: Amniotic fluid analytes evaluated following suspicious screening or ultrasound findings.
- Emerging Molecular Biomarkers: Genetic, epigenetic, and transcriptomic signatures defining underlying pathogenetic pathways.

Source and Kinetics: AFP is a glycoprotein produced sequentially by the embryonic yolk sac, fetal liver, and gastrointestinal tract. It peaks in fetal serum near the end of the first trimester and leaks directly across open fetal membranes into the amniotic fluid, subsequently crossing into the maternal circulation via transplacental diffusion.
Maternal Serum AFP (MSAFP):
- Timing: Optimally sampled between 15 and 20 weeks of gestation (second trimester).
- Reporting: Expressed in Multiples of the Median (MoM) to normalize variations across gestational age, maternal weight, race, and diabetic status.
- Cut-off Limits: An MSAFP value $\geq 2.0$ or $2.5 MoM$ is highly indicative of an open NTD (anencephaly or open spina bifida).
- Sensitivity: Detects approximately 80% of open spina bifida cases and over 90% of anencephaly cases.
Amniotic Fluid AFP (AFAFP):
- Indication: Utilized as a secondary test following an elevated MSAFP or suspicious fetal ultrasonography.
- Significance: An elevated AFAFP ( $> 2.0 MoM$ ) strongly suggests a structural fetal defect, demonstrating near-absolute sensitivity for open NTDs.

Mechanism: AChE is an enzyme crucial for neurohumoral transmission, found in high concentrations within fetal neural tissues. In open NTDs, AChE directly leaches from exposed neurological structures into the amniotic fluid.
Amniotic Fluid AChE (AFAChE):
- Clinical Value: Served as the confirmatory gold standard for open NTDs.
- Specificity: Unlike AFAFP, which can be elevated by fetal blood contamination, fetal death, or abdominal wall defects (e.g., omphalocele), the presence of an AChE band on gel electrophoresis is highly specific for neural tissue exposure.

Rapidly Adherent (RA) Cells: Amniotic fluid from pregnancies complicated by open NTDs contains a distinct population of phagocytic, macrophage-like, or neural-derived cells that adhere rapidly to culture plates within 20–30 hours.
Immunofluorochemical Profiling: These cells stain strongly positive for neural-specific cytoskeletal filaments, such as Glial Fibrillary Acidic Protein (GFAP) and Neurofilament proteins, confirming their neuroectodermal origin.

Maternal Serum Folate: Low maternal folate levels act as a significant susceptibility biomarker, directly increasing the relative risk of developing an NTD.
Maternal Erythrocyte (RBC) Folate: Reflects long-term tissue folate stores during the critical window of neural tube closure. Red blood cell folate levels $< 906 nmol/L$ ( $400 ng/mL$ ) represent a high-risk threshold.
Total Plasma Homocysteine (tHcy): Elevated maternal periconceptional serum homocysteine levels serve as a functional biomarker for impaired intracellular methylation and compromised folate metabolism.

Folate Receptor Alpha (FR $α$ ) Autoantibodies: Circulating maternal autoantibodies that bind and block FR $α$ inhibit the active transport of folate across the placenta into the developing embryo, acting as an immunological biomarker for increased NTD risk.

MTHFR Gene Mutations: The $C 677 T$ and $A 1298 C$ single nucleotide polymorphisms (SNPs) in the Methylenetetrahydrofolate Reductase gene lead to thermolabile enzyme variants with significantly reduced capacity to generate 5-methyltetrahydrofolate.
Other Pathway Genes: Biomarker mutations in MTHFD1, MTR, and MTRR genes highlight structural vulnerabilities in the embryonic folate-dependent one-carbon metabolism network.

DNA Methylation Profiles: Altered global and gene-specific DNA methylation signatures in fetal tissues and amniocytes act as regulatory biomarkers. Hypomethylation of neural development genes impairs proper neural tube closure.
Histone Modifications: Specific changes in histone acetylation and methylation patterns within amniotic fluid cells serve as highly sensitive indicators of aberrant neurodevelopmental gene expression.

MicroRNAs (miRNAs): Distinct profiles of cell-free microRNAs (such as miRNA-10a, miRNA-19b, and miRNA-145) isolated from maternal plasma or amniotic fluid function as stable transcriptomic biomarkers. They regulate targeted apoptotic and proliferative signaling pathways during spinal cord neurulation.